Zhaoke Ophthalmology Limited disclosed that it repurchased 1.16 million ordinary shares between 11 and 22 June 2026 under its board-approved buyback mandate dated 15 May 2026. The purchases were executed on the Stock Exchange of Hong Kong at prices ranging from HKD 2.54 to HKD 2.83 per share.

Key figures • Shares repurchased for cancellation (not yet cancelled): – 11 Jun 2026: 174,000 shares at HKD 2.72 each – 15 Jun 2026: 56,500 shares at HKD 2.82 each – 16 Jun 2026: 615,000 shares at HKD 2.83 each – 22 Jun 2026: 318,500 shares at HKD 2.54 each, costing HKD 0.81 million

• Cumulative shares repurchased under the mandate: 1.16 million, representing 2.12 % of the 54.87 million shares authorised for buyback.

• Post-transaction share capital: 548.75 million issued shares; no treasury shares were held as at 22 June 2026 because the repurchased shares had yet to be cancelled.

• Moratorium: In line with HKEX rules, Zhaoke Ophthalmology is restricted from issuing new shares or selling treasury shares until 22 July 2026.

All repurchases were conducted in accordance with the Hong Kong Main Board Listing Rules, and the company confirmed receipt of all funds and full regulatory compliance.